Loading
Led COG AALL1731, which showed adding blinatumomab to chemotherapy improves survival for children with standard-risk leukaemia.
Sumit Gupta was study chair of Children's Oncology Group AALL1731, the randomised trial showing that adding the CD19 bispecific blinatumomab to chemotherapy dramatically improves disease-free survival in children with newly diagnosed standard-risk B-cell acute lymphoblastic leukaemia, the largest advance in front-line childhood ALL in decades. He also studies disparities and outcomes in paediatric cancer at SickKids.
| Title | Journal | Year |
|---|---|---|
| Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children (AALL1731) | NEJM | 2025 |
| Pediatric cancer outcomes and socioeconomic status: population-based studies | Cancer | 2016 |
| Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL | New England Journal of Medicine | 2025 |
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, Acute lymphoblastic leukaemia and the tags paediatric, all.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific) and the tags all, immunotherapy.
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD19.
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD19.
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag all.
Shares Acute lymphoblastic leukaemia and the tags paediatric, all.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD19 and the tag paediatric.